Patents by Inventor Piyasena Hewawasam

Piyasena Hewawasam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds useful as immunomodulators
    Patent number: 10745382
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: August 18, 2020
    Assignee: bristol-myers squibb company
    Inventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • Hepatitis C virus inhibitors
    Patent number: 10617675
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: David B. Frennesson, Piyasena Hewawasam, Omar D. Lopez, Van N. Nguyen, Mark G. Saulnier, Yong Tu, Alan Xiangdong Wang, Gan Wang, Ningning Xu, Roshan Yadavrao Nimje, Hasibur Rahaman, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell, Makonen Belema
  • Compounds useful as immunomodulators
    Patent number: 10144706
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 4, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20180221342
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Inventors: David B. Frennesson, Piyasena Hewawasam, Omar D. Lopez, Van N. Nguyen, Mark G. Saulnier, Yong Tu, Alan Xiangdong Wang, Gan Wang, Ningning Xu, Roshan Yadavrao Nimje, Hasibur Rahaman, Samayamunthula Venkata Satya Arun Kumar Gupta, Nicholas A. Meanwell, Makonen Belema
  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20180057455
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: August 29, 2017
    Publication date: March 1, 2018
    Inventors: KAP-SUN YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
  • Compounds useful as immunomodulators
    Patent number: 9850225
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: December 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Louis S. Chupak, Min Ding, Scott W. Martin, Xiaofan Zheng, Piyasena Hewawasam, Timothy P. Connolly, Ningning Xu, Kap-Sun Yeung, Juliang Zhu, David R. Langley, Paul Michael Scola
  • HEPATITIS C VIRUS INHIBITOR
    Publication number: 20170355689
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: August 29, 2017
    Publication date: December 14, 2017
    Inventors: RICO LAVOIE, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • Hepatitis C virus inhibitors
    Patent number: 9776981
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 3, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Rico Lavoie, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • Hepatitis C virus inhibitors
    Patent number: 9770439
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: September 26, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema
  • COMPOUNDS USEFUL AS IMMUNOMODULATORS
    Publication number: 20170107202
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 20, 2017
    Inventors: KAP-SUN YEUNG, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • HEPATITIS C VIRUS INHIBITORS
    Publication number: 20160199355
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: March 11, 2016
    Publication date: July 14, 2016
    Inventors: PIYASENA HEWAWASAM, JOHN F. KADOW, OMAR D. LOPEZ, NICHOLAS A. MEANWELL, YONG TU, ALAN XIANGDONG WANG, NINGNING XU, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR GUPTA, POTHUKANURI SRINIVASU, INDASI GOPI KUMAR, PONUGUPATI SURESH KUMAR, MAKONEN BELEMA, ROBERT A. FRIDELL, MIN GAO, JULIE A. LEMM, DONALD R. O'BOYLE, II, JIN-HUA SUN, CHUNFU WANG, YING-KAI WANG
  • Combinations of Hepatitis C Virus Inhibitors
    Publication number: 20160158200
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 9, 2013
    Publication date: June 9, 2016
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Punugupati, Makonen Belema
  • Hepatitis C virus inhibitors
    Patent number: 9326973
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: May 3, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, John F. Kadow, Omar D. Lopez, Nicholas A. Meanwell, Yong Tu, Alan Xiangdong Wang, Ningning Xu, Samayamunthula Venkata Satya Arun Kumar Gupta, Pothukanuri Srinivasu, Indasi Gopi Kumar, Ponugupati Suresh Kumar, Makonen Belema, Robert A. Fridell, Min Gao, Julie A. Lemm, Donald R. O'Boyle, II, Jin-Hua Sun, Chunfu Wang, Ying-Kai Wang
  • Hepatitis C Virus Inhibitors
    Publication number: 20150322048
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: July 23, 2015
    Publication date: November 12, 2015
    Inventors: Rico Lavoie, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • Hepatitis C Virus Inhibitors
    Publication number: 20150297568
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: June 29, 2015
    Publication date: October 22, 2015
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamunthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema
  • Compounds Useful as Immunomodulators
    Publication number: 20150291549
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: April 8, 2015
    Publication date: October 15, 2015
    Inventors: Louis S. Chupak, Min Ding, Scott W. Martin, Xiaofan Zheng, Piyasena Hewawasam, Timothy P. Connolly, Ningning Xu, Kap-Sun Yeung, Juliang Zhu, David R. Langley, Daniel J. Tenney, Paul Michael Scola
  • Hepatitis C Virus Inhibitors
    Publication number: 20150197499
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: March 25, 2015
    Publication date: July 16, 2015
    Inventors: Rico Lavoie, John A. Bender, Zhong Yang, Makonen Belema, Omar D. Lopez, Qi Chen, Gan Wang, Piyasena Hewawasam
  • Hepatitis C Virus Inhibitors
    Publication number: 20150023913
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Application
    Filed: July 2, 2013
    Publication date: January 22, 2015
    Inventors: Piyasena Hewawasam, Omar D. Lopez, Yong Tu, Alan Xiangdong Wang, Ningning Xu, John F. Kadow, Nicholas A. Meanwell, Samayamuthula Venkata Satya Arun Kumar Gupta, Indasi J. Gopi Kumar, Suresh Kumar Ponugupati, Makonen Belema
  • Hepatitis C virus inhibitors
    Patent number: 8796466
    Abstract: This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: August 5, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: John A. Bender, Piyasena Hewawasam, John F. Kadow, Omar D. Lopez, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Lawrence B. Snyder, Denis R. St. Laurent, Gan Wang, Ningning Xu, Makonen Belema
  • Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors
    Publication number: 20140186299
    Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 3, 2014
    Inventors: John A. Bender, Min Ding, Robert G. Gentles, Piyasena Hewawasam